NEUP (Neuphoria) Business Value to Revenue

Public company logo of Neuphoria (NEUP)

The EV/Sales trend for Neuphoria Therapeutics Inc. (NEUP) demonstrates volatility, where the value -5264.96 describes the current level. This price action is driven by the testing stage of new drugs and partnership revenues. Meanwhile, a high dependency on the success of a narrow range of molecules creates binary risks. A strong staff of neurobiologists, motivated by an ethical mission and generous stock options, supports the company's stability.

NEUP (Neuphoria Therapeutics) EV/Sales Multiple history from 11/23/2025 to 11/20/2026

NEUP (Neuphoria Therapeutics): analytical breakdowns and indicator data

- current quotes and average value forecast:
- money and cash flow information:
Fundamental company valuation:NEUP - Neuphoria
Core merchandise of bionomics.com.au

Neuphoria Therapeutics Inc. (NEUP) development is complicated by geopolitical instability, which disrupts biocomponent logistics and the conduct of international clinical trials. An analysis of EV/Sales historical trends allows for a business valuation that accounts for net debt relative to revenue, determining the asset's current overvaluation. This indicator helps investors understand whether historical valuation boundaries provide capital protection amidst global economic shocks.

Competitor analysis

BIIB (Biogen Inc.) - Company Value to Revenue Ratio|NBIX: EV/Sales Multiple|RGC (Regencell Bioscience Holdings Limited) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Axsome Therapeutics Inc|ACAD: Business Value to Revenue|EV/Sales Multiple XENE|EV/Sales Multiple vikingtherapeutics.com (VKTX)|Enterprise Value-to-Revenue Ratio Supernus SUPN|Business Value to Revenue CPRX|denalitherapeutics.com - EV/Sales Multiple|Total Company Value-to-Revenue Ratio Harmony Pharma HRMY|BHVN: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Amylyx Pharmaceuticals, Inc. (AMLX)|TRVI (Trevi Therapeutics Inc) - EV/Sales Multiple|Company Value to Revenue Ratio PRAX (Praxis Medicines)|Enterprise Value-to-Revenue Ratio Anavex Life Sciences (AVXL)|Enterprise Value-to-Revenue Ratio CBLL (CeriBell EEG)|EV/Sales Multiple PRTA (Prothena Corp)|alector.com (ALEC) - Enterprise Value-to-Revenue Multiple|ANNX: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Omeros|NGNE: EV/Sales Multiple|Company Value to Revenue AC Immune|Company Value to Revenue VYGR|Company Value to Revenue Ratio NMRA (neumoratx.com)|Company Value to Revenue SCLX (Scilex Holding Company, Inc.)|Enterprise Value-to-Revenue Ratio TVGN (Tevogen Bio)|Enterprise Value-to-Revenue Ratio Alpha Cognition ACOG|CGTX - Company Value to Revenue|IKT - Enterprise Value-to-Revenue Ratio|SAVA: Enterprise Value-to-Revenue Ratio|Assertio Therapeutics (ASRT) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Coya Therapeutics Inc (COYA)|Enterprise Value-to-Revenue Ratio Vistagen|Company Value to Revenue Ratio OVID (ovidrx.com)|Enterprise Value-to-Revenue Ratio Acumen Pharmaceuticals, Inc. (ABOS)|CRVO - Enterprise Value-to-Revenue Multiple|Alterity Therapeutics Ltd. - Company Value to Revenue|CLNN - Company Value to Revenue|PEPG - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio jupiterneurosciences.com JUNS|Relmada Therapeutics (RLMD) - Enterprise Value-to-Revenue Ratio|ANVS (Annovis Bio, Inc.) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio gracetx.com|EV/Sales Multiple Firefly Neuroscience, Inc.|Enterprise Value-to-Revenue Ratio ANEW Medical (KLTO)|NRSN - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple RVPH (Reviva Pharmaceuticals Holdings Inc.)|Enterprise Value-to-Revenue Coefficient MTVA (metaviatx.com)|NeurAxis Inc. - EV/Sales Multiple|Total Company Value-to-Revenue Ratio heliusmedical.com HSDT|PASG: EV/Sales Multiple|Minerva Neurosciences - Business Value to Revenue|ATHA (Athira Pharma, Inc.) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple addextherapeutics.com ADXN|Company Value to Revenue ALZN (Alzamend Neuro Inc.)|CYCN (Cyclerion Therapeutics, Inc.) - Business Value to Revenue|EV/Sales Multiple PTIX (Protagenic)|EV/Sales Multiple pasitheaclinics.com KTTA|CRGT - Enterprise Value-to-Revenue Ratio|Business Value to Revenue ATXI (Avenue Therapeutics)|BCLI: EV/Sales Multiple|Cara Therapeutics - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Chromocell Therapeutics Corporation|EV/Sales Multiple Eliem Therapeutics Inc.|Enterprise Value-to-Revenue Ratio Intra-Cellular Therapies, Inc. (ITCI)|LBPH (Longboard Pharmaceuticals) - Business Value to Revenue|EV/Sales Multiple MRNS (marinuspharma.com)|NKGN: Company Value to Revenue Ratio|NRBO - Enterprise Value-to-Revenue Ratio|SAGE - EV/Sales Multiple|Synaptogenix (SNPX) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Trevena (TRVN)|Company Value to Revenue VIGL|Company Value to Revenue Ratio WENA (Anew Medical)|EV/Sales Multiple CERE